Rosuvastatin in the Treatment of Rectal Cancer
- First Posted Date
- 2015-10-07
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 45
- Registration Number
- NCT02569645
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients
Phase 1
Withdrawn
- Conditions
- Metastatic Solid MalignanciesLocally Advanced Solid Malignancies
- Interventions
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- AHS Cancer Control Alberta
- Registration Number
- NCT02439723
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib
Withdrawn
- Conditions
- Renal Cell CancerFatigue
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- AHS Cancer Control Alberta
- Registration Number
- NCT02428335
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Chemoradiotherapy for Advanced Esophageal Cancer
Phase 2
Recruiting
- Conditions
- Esophageal Cancer
- Interventions
- Radiation: External Beam Radiation
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 50
- Registration Number
- NCT02297217
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma
Phase 1
Terminated
- Conditions
- Hodgkin's Lymphoma - Relapsed/RefractoryNon-Hodgkin's Lymphoma - AggressiveFollicular Lymphoma
- Interventions
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 100
- Registration Number
- NCT02295722
- Locations
- 🇨🇦
Tom Baker Cancer Center, Calgary, Alberta, Canada
A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers
Phase 2
Active, not recruiting
- Conditions
- Estrogen Receptor Positive Breast Cancer
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 19
- Registration Number
- NCT02238808
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Trial of Hypofractionated Radiation Therapy for Glioblastoma
Phase 2
Completed
- Conditions
- Glioblastoma
- Interventions
- Radiation: Standard radiation therapyRadiation: Hypofractionated radiation therapy
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 133
- Registration Number
- NCT02206230
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Studying if Adding Night Compression to Standard Care Will Have Improved Control of Lymphedema in Breast Cancer Subjects
Not Applicable
Completed
- Conditions
- Breast CancerLymphedema
- Interventions
- Device: Compression Sleeve, daytime wearDevice: Night-time compression bandagesDevice: Night-time Compression custom-made garment
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 120
- Registration Number
- NCT02187289
- Locations
- 🇨🇦
Mount St. Joseph Hospital/Holy Family (MSJ/HF), Vancouver, British Columbia, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦Tom Baker Cancer Centre, Calgary, Alberta, Canada
A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2016-07-06
- Lead Sponsor
- AHS Cancer Control Alberta
- Registration Number
- NCT02152059
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
Phase 1
Terminated
- Conditions
- Non-small Cell Lung CancerAdvanced Solid Malignancies
- Interventions
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2019-05-03
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 15
- Registration Number
- NCT02080078
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
© Copyright 2025. All Rights Reserved by MedPath